


Edited by
Graham Dellaire
Jason Berman
Robert Arceci



Cancer Genomics

From Bench to Personalized Medicine



Cancer Genomics

From Bench to Personalized Medicine

Edited by

Graham Dellaire, Ph.D.


Departments of Pathology and Biochemistry &
Molecular Biology Dalhousie University, Halifax, Canada

Jason. N. Berman, M.D., FRCPC, FAAP

IWK Health Centre, Departments of Pediatrics,
Pathology and Microbiology and Immunology
Dalhousie University, Halifax, Canada

Robert J. Arceci, M.D., Ph.D.

The Ron Matricaria Institute of Molecular Medicine at
Phoenix Childrens Hospital, Department of Child Health,
University of Arizona, College of Medicine,
Phoenix, USA



AMSTERDAM • BOSTON • HEIDELBERG • LONDON
NEW YORK • OXFORD • PARIS • SAN DIEGO
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier
32 Jamestown Road, London NW1 7BY, UK
225 Wyman Street, Waltham, MA 02451, USA
525 B Street, Suite 1800, San Diego, CA 92101-4495, USA

Copyright © 2014 Elsevier Inc. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher.

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: mailto:hpermissions@elsevier.com. Alternatively, visit the Science and Technology Books website at www.elsevierdirect.com/rights for further information.

Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

ISBN : 978-0-12-396967-5

For information on all Academic Press publications
visit our website at www.store.elsevier.com

Typeset by MPS Limited, Chennai, India
www.adi-mps.com

Printed and bound in United States of America

14 15 16 17 18 10 9 8 7 6 5 4 3 2 1

		Working together to grow libraries in developing countries
www.elsevier.com • www.bookaid.org		

Cancer Genomics

From Bench to Personalized Medicine



ELSEVIER
*science &
technology books*



Companion Web Site:

<http://store.elsevier.com/product.jsp?&isbn=9780123969675>

Cancer Genomics: From Bench to Personalized Medicine

Graham Dellaire, Jason N. Berman and Robert J. Arceci, Editors

Resources available:

- All figures from the book available as both Power Point slides and .jpeg files
- Links to web sites carefully chosen to supplement the content of the textbook
- Contact the editors with questions and/or suggestions



ACADEMIC
PRESS

List of Contributors

- Kenneth C. Anderson** Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA, USA
- Samuel A. Aparicio** British Columbia Cancer Agency, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
- Robert J. Arceci** Children's Center for Cancer and Blood Disorders, Hematology/Oncology and The Ron Matricaria Institute of Molecular Medicine, Phoenix Children's Hospital, Department of Child Health, University of Arizona, College of Medicine, Phoenix, AZ, USA
- Alejandro Berlin** Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Toronto, ON, Canada; Ontario Cancer Institute and Princess Margaret Cancer Center (University Health Network), Toronto, ON, Canada
- Jason N. Berman** Departments of Pediatrics, Microbiology and Immunology, and Pathology, Dalhousie University and IWK Health Centre, Halifax, NS, Canada
- Maria Grazia Borrello** Molecular Mechanisms Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Robert G. Bristow** Ontario Cancer Institute and Princess Margaret Cancer Center (University Health Network), Toronto, ON, Canada; Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Toronto, ON, Canada
- Moamen Bydoun** Department of Pathology, Dalhousie University, Halifax, NS, Canada
- George A. Calin** Department of Experimental Therapeutics and Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Priscilla P.L. Chiu** Department of Surgery, The Hospital for Sick Children, Toronto, ON, Canada
- Hye-Jung E. Chun** British Columbia Cancer Agency, Vancouver, BC, Canada; Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada
- Francesca Cottini** Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA, USA
- Janet E. Dancey** Ontario Institute for Cancer Research, Toronto, ON; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada
- Graham Dellaire** Departments of Pathology and Biochemistry & Molecular Biology, Dalhousie University, Halifax, NS, Canada
- Amal M. EL-Naggar** Department of Molecular Oncology, BC Cancer Research Center, Vancouver, BC; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Conrad V. Fernandez** Departments of Pediatrics and Bioethics, Head, Division of Pediatric Hematology/Oncology, Dalhousie University and IWK Health Centre, Halifax, NS, Canada
- Michael Fraser** Ontario Cancer Institute and Princess Margaret Cancer Center (University Health Network), Toronto, ON, Canada
- Daniel Gaston** Department of Pathology, Dalhousie University, Halifax, NS, Canada
- Carman Giacomantonio** Departments of Pathology and Surgery, Dalhousie University, Halifax, NS, Canada
- Angela Greco** Molecular Mechanisms Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Erin Hedlund** Computational Biology Department, St Jude Children's Research Hospital Memphis, TN, USA
- Matthew Herder** Health Law Institute, Faculties of Medicine and Law, Dalhousie University, Halifax, NS, Canada
- Peter Hohenstein** The Roslin Institute, University of Edinburgh, Easter Bush Campus, Midlothian, UK

- Meredith S. Irwin** Department of Paediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
- Steven J.M. Jones** Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada
- Katayoon Kasaian** Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada
- Javed Khan** Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Bethesda, MD, USA
- Jaswinder Khattri** British Columbia Cancer Agency, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
- Martin Krzywinski** British Columbia Cancer Agency, Vancouver, BC, Canada; Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada
- Cécile Le Page** Centre hospitalier de l'Université de Montréal, Institut du Cancer de Montréal, Montreal, QC, Canada
- Gabriel Leprivier** Department of Molecular Oncology, BC Cancer Research Center, Vancouver, BC; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Yvonne Y. Li** Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada
- Hui Ling** Department of Experimental Therapeutics and Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Anthony M. Magliocco** H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
- David Malkin** Division of Hematology/Oncology, The Hospital for Sick Children and Department of Pediatrics, University of Toronto, Toronto, ON, Canada
- Branavan Manoranjan** McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
- Paola Marcato** Department of Pathology, Dalhousie University, Halifax, NS, Canada
- Marco A. Marra** British Columbia Cancer Agency, Vancouver, BC, Canada; Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada
- Anne-Marie Mes-Masson** Université de Montréal, Department of Medicine, Montreal, QC, Canada; Centre hospitalier de l'Université de Montréal, Institut du Cancer de Montréal, Montreal, QC, Canada
- Soheil Meshinchi** Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
- Claudia Miranda** Molecular Mechanisms Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Stephen B. Montgomery** Departments of Pathology and Genetics, Stanford University, Stanford, CA, USA
- Daniel A. Morgenstern** Department of Paediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
- Ryan D. Morin** Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
- Veronique Ouellet** Centre de Recherche du Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada
- Louise Parker** Departments of Medicine and Pediatrics, Dalhousie University, Halifax, NS, Canada
- Matthew Parker** Computational Biology Department, St Jude Children's Research Hospital Memphis, TN, USA
- Elizabeth J. Perlman** Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- Marco A. Pierotti** Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Shahrad Rod Rassekh** Child and Family Research Institute, British Columbia's Children's Hospital, Vancouver, BC, Canada; Department of Pediatrics, Division of Pediatric Hematology/Oncology/BMT, University of British Columbia, Vancouver, BC, Canada
- Colin J.D. Ross** Child and Family Research Institute, British Columbia's Children's Hospital, Vancouver, BC, Canada; Department of Pediatrics, Division of

Translational Therapeutics, University of British Columbia, Vancouver, BC, Canada; Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada

Fred Saad Department of Surgery, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada; Montreal Cancer Institute, Montreal, QC, Canada

Sheila K. Singh McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada; Surgery, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada

Poul H. Sorensen Department of Molecular Oncology, BC Cancer Research Center, Vancouver, BC; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada

Giovanni Tonon Division of Molecular Oncology, Functional Genomics of Cancer Unit, San Raffaele Scientific Institute, Milan, Italy

Chitra Venugopal McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada

Parvez Vora McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada

Jun S. Wei Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Bethesda, MD, USA

Zhaolin Xu Department of Pathology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

Jinghui Zhang Computational Biology Department, St Jude Children's Research Hospital Memphis, TN, USA

Shile Zhang Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Bethesda, MD, USA; Program in Bioinformatics, Boston University, Boston, MA, USA

List of Contributors

xiii

Part 1 Introduction

1. Historical Perspective and Current Challenges of Cancer Genomics

Graham Dellaire and Robert J. Arceci

A Historical Perspective on the Development of Cancer Genomics

Current and Future Challenges

Glossary

Abbreviations

References

4
7
8
8
8

Part 2 Genomics Technologies, Concepts and Resources

2. Second-Generation Sequencing for Cancer Genome Analysis

Hye-Jung E. Chun, Jaswinder Khattri, Martin Krzywinski, Samuel A. Aparicio and Marco A. Marra

Introduction

Cancer Characterization Using Sequencing

Approaches

Cancer Is a Genetic Disease

Cancer Properties Are Amenable to

Second-Generation Sequence Analysis

Impact of Tumor Heterogeneity on Clinical Diagnosis and Treatments

Advances in Sequencing Technologies

First- and Second-Generation Sequencing Technologies

Progress in Cancer Genomics Research Using Sequencing Approaches

14
15
15
15
16
16
17
18

Applications of Second-Generation Sequencing Technologies

Discoveries Using Second-Generation Sequencing Technologies

Novel Properties of Cancer

Novel Biomarkers and Therapeutic Targets

Development of Personalized Medicine

Future of Cancer Genome Sequencing

Third-Generation Sequencing

Technologies

Clinical Application of Second-Generation Sequencing

Single Cell Genotyping of Bulk Tumors

Conclusion

Glossary

Acronyms and Abbreviations

References

21
21
21
23
23
23
24
24
25
26
26
27
27

3. Cancer Transcriptome Sequencing and Analysis

Ryan D. Morin and Stephen B. Montgomery

Introduction

Cancer Transcriptome Sequencing

Experimental Designs

Archival Samples

Handling Tissue Heterogeneity

Cancer Transcriptome Analysis

RNA-Sequencing Data and Analysis Pipelines

Assessing Differential Expression

Quantifying Allele-Specific Expression

Interpreting Cancer Genome-Wide

Association Studies

Detecting Fusion Transcripts

Identifying Somatic Single Nucleotide Variants

Identifying Pathogen Presence in Cancer Samples

Future Prospects

Acknowledgments

Glossary

Abbreviations

References

32
33
33
35
35
36
36
37
38
39
39
41
42
42
43
43
44
44

4. The Significance of Transcriptome Sequencing in Personalized Cancer Medicine

Shile Zhang, Jun S. Wei and Javed Khan

Why Is RNA Important?	50
From Microarray to RNA Sequencing	50
Workflow for RNA-Seq	51
RNA-Seq Data Analysis in Cancer	
Genome Research	52
Gene Expression Analysis	52
Post-Transcriptional Regulation Analysis	55
Computational Approaches for RNA-Seq Analysis	56
Incorporating Transcriptome-Sequencing Analysis to Identify Genomic Driver Mutations	56
Transcriptome Sequencing: From Bench to Bedside	57
Glossary	61
Abbreviations	61
References	61

5. Tissue Microarrays in Studying Gynecological Cancers

Cécile Le Page, Anne-Marie Mes-Masson and Anthony M. Magliocco

Introduction	66
Materials and Tissues	67
Instruments	67
Tissues	68
Ethics and Regulatory Issues	69
Design of Microarrays	69
Methods and Construction	70
Selection of Tissues and Cores	70
Cutting Slides	71
Antigen Retrieval	71
Staining	71
<i>In Situ</i> Hybridization and Fluorescence	
<i>In Situ</i> Hybridization (ISH and FISH)	72
Quality Control and Analysis	72
Slide Conservation and Storage	72
Staining and Antibody Quality	72
Scoring and Analysis	73
Conclusion	74
Glossary	74
Abbreviations	74
References	75

6. Cancer Pharmacogenomics in Children

Shahrad Rod Rassekh and Colin J.D. Ross

Introduction	78
History of Adverse Drug Reactions in Pediatric Oncology	78
Adverse Drug Reactions	78
Pharmacogenomics	79
Pharmacogenomics of Thiopurine-Induced Toxicity in Children	79
Pharmacogenomics of Methotrexate-Induced Toxicity in Children	81
Pharmacogenomics of Cisplatin-Induced Toxicity	83
Pharmacogenomics of Vincristine-Induced Toxicity	84
Pharmacogenomics of Anthracycline-Induced Cardiac Toxicity	84
Need for Collaboration, Active ADR Surveillance and Future Directions	85
Conclusion	87
Acknowledgments	87
Glossary	87
Abbreviations	88
References	88

7. Biomarker Discovery and Development through Genomics

Janet E. Dancey

Uses of Biomarkers in Cancer Research and Cancer Care	94
Biomarker Discovery and Qualification	95
Important Disclosures during Biomarker Qualification	98
Assay Validation	98
The Phases of Assay Analytical Validation	99
Clinical Validity	100
Retrospective and Prospective Clinical Validation	100
Clinical Utility	101
Guidelines for Assessing Clinical Utility	101
Incorporation of Biomarkers into Clinical Trial Design	102
Designing Clinical Trials to Determine Clinical Utility of Biomarkers	102
Conclusion	103
Glossary	104
Abbreviations	105
References	105

8. Preclinical Animal Models for Cancer Genomics

*Jason N. Berman, Priscilla P.L. Chiu
and Graham Dellaire*

History of the Development of Animal Models for Cancer Research	110
Rodent Animal Models	110
Other Animal Models	112
Transgenic Animal Models	115
Transgenic Mice – GEMMs and nGEMMs	115
Transgenic Zebrafish	118
Xenograft Animal Models	119
Mouse Xenografts	119
Chicken Chorioallantoic Membrane Model	121
Zebrafish Xenografts	121
Important Considerations in Choosing a Xenograft Approach	122
Choosing an Animal Model	124
Advantages and Drawbacks of Various Animal Models	124
Xenografts vs Transgenic Models in Mice and Zebrafish	124
Conclusions	125
Glossary	125
Abbreviations	126
References	126

9. Bioinformatics for Cancer Genomics

*Katayoon Kasaian, Yvonne Y. Li and
Steven J.M. Jones*

Introduction	134
Data Types in Cancer Genomics	134
Whole Genome and Exome Sequence Data	134
Whole Transcriptome Sequence Data	135
Proteomic Data	136
Epigenomic Data	136
Data Management	137
Data Analysis	137
Computational Resources	137
Analysis Algorithms and Tools	138
Analytical Tools	140
Data Interpretation	140
Data Integration	144
Conclusion	146
Glossary	147
Abbreviations	148
References	148

10. Genomic Resource Projects

*Matthew Parker, Erin Hedlund
and Jinghui Zhang*

Introduction: The Genomic Data Goldmine	154
Key Large-Scale Cancer Genomics Projects	156
The Cancer Genome Atlas (TCGA)	156
Other Genomics Projects of Note	158
Catalogue of Somatic Mutations in Cancer (COSMIC) and dbSNP	158
Exome Variant Server (EVS)	158
1000 Genomes Project	158
Data Sources	158
Archives	159
Portals	159
Processors	161
Online/Offline Analysis Tools	161
cBio Cancer Genomics Portal (MSKCC)	161
PCGP “Explore”	163
Galaxy	163
BioMart	165
My Cancer Genome	166
Standalone Genome Sequencing Viewers: IGV and More. . .	166
Cloud Computing	166
Synopsis and Prospects (Genomic Resources and the Clinic)	168
Glossary	169
Abbreviations	170
References	170

Part 3 Hereditary Cancer Syndromes

11. Genetic Basis of Hereditary Cancer Syndromes

David Malkin

Introduction	176
Retinoblastoma	176
Wilms Tumor	178
Non-Syndromic Tumors and Susceptibility Loci	179
Neuroblastoma	179
Sarcomas of Childhood	180
Cancer Predisposition Syndromes	180
Cancer Predisposition Syndromes with Malignant-Only Phenotype	180

Cancer Predisposition Syndromes with Coincident Congenital Anomalies	185
Molecular and Clinical Surveillance for Cancer Predisposition in Children	186
The Potential Impact of Genome Studies on Hereditary Cancer Syndromes	187
Glossary	187
Abbreviations	187
References	188

Part 4

Genomics of Adult and Pediatric Cancers

4.1

Adult Solid Tumors

12. Genomics and Molecular Profiling of Lung Cancer

Zhaolin Xu

Introduction	194
Epidemiology	195
Standard Treatment of Lung Cancer and Prognosis	195
Surgery	195
Radiation Therapy	195
Chemotherapy	195
Personalized Targeted Therapy	196
Laser Therapy	196
Photodynamic Therapy	196
Cryotherapy	196
Electrocautery	196
Somatic Gene Mutations in Lung Cancer	196
Pathogenesis of Lung Cancer	196
Molecular Profiling in Lung Cancer	198
Common Gene Mutations and Clinical Significance	198
KRAS	198
EGFR	200
ALK	200
BRAF	201
PIK3CA	201
HER2	202
MET	202
Personalized Targeted Therapy in Lung Cancer	202
Selection of Targets	202
EGFR Tyrosine Kinase Inhibitors	202
Inhibitor against EML4–ALK Fusion Gene	204
Inhibitors against MET Gene Mutation/Amplification	204

Other Inhibitors against Gene Mutations	204
Acquired Resistance and Secondary Mutations	204
Glossary	205
References	207

13. Breast Cancer Genomics

*Moamen Bydoun, Paola Marcato
and Graham Dellaire*

Introduction	214
Breast Cancer Epidemiology	214
Breast Anatomy and Development	214
Hormonal Regulation and Predisposition to Transformation	214
Breast Cancer Development and Progression: A Step-Wise Phenomenon	215
Germline and Somatic Aberrations	215
Epigenetic Dereglulation	216
Breast Cancer Diagnosis and Prognosis: A Historical Overview	218
Clinical Diagnosis and Prognosis	218
Gene Expression Signatures	218
Genomic Signatures	222
Future of Breast Cancer Prognosis and Treatment	226
Feasibility of Molecular/Genomic Signatures in Clinical Practice	226
Non-Invasive Monitoring of Residual and Occult Disease	226
Need for Standardization and Personalized Medicine	226
Acknowledgments	227
Glossary	227
Abbreviations	228
References	229

14. Prostate Cancer Genomics as a Driver of Personalized Medicine

*Michael Fraser, Alejandro Berlin, Veronique
Ouellet, Fred Saad and Robert G. Bristow*

The Need for Genomics in Prostate Cancer Prognosis	234
Genetic Architecture of Prostate Cancer and Clinical Outcome	235
Genetics of Prostate Cancer Risk	236
Genetics of Localized Disease through to Metastases	236
The Special Case of BRCA1/2-Mutated Tumors	237
Defining Heterogeneity in Prostate Cancer: Multifocality and Multiclonality	237

Genome-Wide Sequencing and RNA	
Expression Studies: Developing Signatures	
of Clinical Utility	238
Conclusions: Transferring Genomic	
Information into Clinical Tests	241
Acknowledgments	241
Glossary	242
Abbreviations	243
References	243

15. Genomics of Colorectal Cancer

Daniel Gaston and Carman Giacomantonio

Introduction	248
Colorectal Cancer Syndromes	249
Lynch Syndrome and the Mismatch	
Repair System	250
Familial Adenomatous Polyposis	251
Other Hereditary CRC Syndromes	251
Genomic Features of Colorectal Cancer	
and Genome-Wide Analyses	251
Epigenomics	252
Genome-Wide Association Studies of	
Colorectal Cancer Susceptibility	253
Exome/Genome Sequencing and the	
Identification of Common Somatic	
Mutations	253
Structural Variation	254
Transcriptomics	254
Impact of Common Somatic Mutations	
on Molecular Pathways in	
Colorectal Cancer	256
Molecular Diagnostics and Treatment	
Guidance	257
Conclusions and Future Directions	258
Glossary	259
Abbreviations	260
References	261

16. Thyroid Cancer

Angela Greco, Claudia Miranda, Maria Grazia Borrello and Marco A. Pierotti

Introduction	266
Papillary Thyroid Carcinoma (PTC)	266
High Frequency of Oncogenic Chromosomal	
Rearrangements in PTC	268
RET/PTC Rearrangements	269
TRK Rearrangements	270
ALK Rearrangements	271
AKAP9/BRAF Rearrangements	271
BRAF Mutations	271
RAS Mutations	272

Follicular Thyroid Carcinoma (FTC)	272
RAS Oncogenes	272
PAX8/PPAR γ Rearrangements	272
Mitochondrial Defects	273
Poorly Differentiated Thyroid Carcinoma	
(PDTC) and Anaplastic Thyroid	
Carcinoma (ATC)	273
Genetic Alterations Shared with DTC	273
Alterations of the PTEN/PI3K/AKT Pathway	273
TP53 Mutations	274
ALK Mutations	274
β -Catenin Mutations	274
Expression Profile Studies in Epithelial Thyroid	
Tumors	274
Gene Expression	274
MicroRNA Expression	275
Medullary Thyroid Carcinoma (MTC)	275
RET Mutations	275
RAS Mutations	276
Conclusions	276
Glossary	276
Abbreviations	277
References	277

4.2

Age Non-specific Tumors and Hematopoietic Malignancies

17. Acute Myeloid Leukemia

Robert J. Arceci, Jason N. Berman and Soheil Meshinchi

Introduction	284
Epidemiology	284
Etiology	285
Mutagenic Environmental Exposures	285
Inherited Predisposition	285
Genetic and Epigenetic Alterations	285
Chromosomal Alterations	286
Chimeric Transcription Factors	286
MLL Gene Rearrangements	286
Miscellaneous Chromosomal Abnormalities	288
Sub-Karyotypic Chromosomal Abnormalities	288
Somatic Mutations and Their Contribution	
to Survival in Childhood AML	288
Disease Associated Mutations in Signal	
Transduction Pathways	288
Insights from Genome-Wide Analysis	291
Epigenetic Changes	292
Transcriptional Alterations	293
Integration of Molecular Datasets and	
Pathway Directed Treatment	293

Conclusion	294	Systematic Sequencing of Medulloblastoma	
Glossary	294	Genome	327
Abbreviations	294	Common Mutations in Medulloblastoma	328
References	294	Epigenetic Alterations in Human Medulloblastoma	330
		Treatment	330
		Heterogeneity	331
18. Genomics in Multiple Myeloma: From Conventional Cytogenetics to Novel Whole Genome Sequencing Approaches		Other Brain Tumors	331
<i>Francesca Cottini, Kenneth C. Anderson, and Giovanni Tonon</i>		Ependymoma	331
Introduction	302	Pediatric Glioblastoma	332
Complex Karyotypes in Multiple Myeloma	303	Diffuse Intrinsic Pontine Glioma	333
Balanced Chromosomal Rearrangements in Multiple Myeloma	304	Conclusion	334
Translocation t(11;14)	304	Glossary	334
Translocation t(4;14)	304	Abbreviations	334
MAF Translocations	305	References	334
Chromosomal Imbalances in Multiple Myeloma	305		
Copy Number Variations with Prognostic Significance	305	4.3 Pediatric Cancers	
Other Common Regions of Copy Number Variations	308	20. Genomic Basis of Pediatric Lymphomas	
Somatic Mutations	309	<i>Nathanael G. Bailey, Thomas Gross and Megan S. Lim</i>	
RAS and FGFR3 Mutations	310	Introduction	342
TP53 Mutations	310	Overview of B-Cell Development	342
Novel Mutations	310	Lymphoblastic Lymphoma	343
Somatic Mutations Stratified by Chromosomal Translocations	312	B-Lymphoblastic Lymphoma	343
Genomic Alterations in MGUS and PCL	312	T-Lymphoblastic Lymphoma	343
Glossary	313	Mature B-Cell Lymphomas	344
Abbreviations	316	Diffuse Large B-Cell Lymphoma	344
References	316	Burkitt Lymphoma	347
		Anaplastic Large Cell Lymphoma	349
19. Brain Tumor Genomics: Sequencing to Clinical Utility		Conclusions and Future Studies	350
<i>Branavan Manoranjan, Parvez Vora, Chitra Venugopal and Sheila K. Singh</i>		Glossary	351
Introduction to Brain Tumors	322	Abbreviations	351
Gliomas	322	References	351
Clinical Presentation and Epidemiology	322		
Classifying Gliomas	323	21. Neuroblastoma	
Systematic Sequencing of Glioblastoma Genome	324	<i>Daniel A. Morgenstern and Meredith S. Irwin</i>	
Common Mutations in GBM	324	Introduction	358
Epigenetic Alterations in Human Gliomas	325	Germline Predisposition	359
Heterogeneity	326	Familial Neuroblastoma	359
Current and Future Therapeutic Approaches	326	Predisposition to Sporadic Neuroblastoma	361
Medulloblastoma	327	Somatic Changes in Neuroblastoma	363
Classifying Medulloblastoma	327	Abnormalities of Specific Genes in Neuroblastoma	363
		ALK	363
		ATRX	364
		ARID1A/1B	364
		PTPN11	364
		MYCN Amplification	364

Chromosomal Abnormalities	365	Wnt Signaling	402
17q Gain	366	IGF2	403
11q Loss	366	Genomics: Bench to Bedside	404
1p Loss	366	Overview	404
Segmental Chromosomal Abnormalities	367	DNA Copy Number Analysis	404
mRNA Expression and Signatures	367	Transcriptomic Analysis	406
<i>Trk</i> Genes	367	Wilms Tumors with Anaplasia	408
mRNA Expression Signatures	367	Next-Generation Sequencing	408
miRNAs	368	Wilms Tumor Cancer Stem Cells	408
Epigenetics	368	Conclusions	409
Host Genomics	370	Glossary	409
Conclusion	371	Abbreviations	410
Glossary	371	References	410
Abbreviations	371		
References	372		
22. Soft Tissue Sarcomas		Part 5	
<i>Amal M. EL-Naggar, Gabriel Leprivier</i>		Ethics of Genomics Research	
<i>and Poul H. Sorensen</i>			
Introduction	378	24. Cancer Genomics and Biobanking:	
Genetics	379	Exploring Key Ethical and Legal Issues	
STSs with Simple Karyotypic Defects	379	<i>Matthew Herder, and Conrad V. Fernandez</i>	
STSs with Complex Karyotypic Defects	381	Introduction	418
Histologic Subtypes of STSs	381	Vignette Part 1: Olivia's Leukemia	418
Rhabdomyosarcoma (RMS)	381	Part 1. The Ethics of Returning Research	
Synovial Sarcoma (SS)	382	Results to Research Participants	419
Gastrointestinal Stromal Tumor (GIST)	383	The Return of Research Results	419
Congenital Fibrosarcoma (CFS)	383	Return of a Summary of Results	419
Extraosseous Ewing Sarcoma (EES)	383	Return of Individual Results	420
Undifferentiated Pleomorphic Sarcoma (UPS)	384	Vignette Part 2: 10 Years after Olivia's	
Leiomyosarcoma (LMS)	384	Donation	424
Liposarcoma (LPS)	384	Part 2. Biobanks and the Commercialization	
Extraosseous Osteosarcoma	385	of Research: Legal and Ethical Issues	424
Molecular Diagnosis of STSs	385	Patenting Human Biological Materials	
Commonly Deregulated Signaling Pathways		and Related Research Findings	425
in STSs	386	The Commercialization of Research and	
Insulin-Like Growth Factor 1 Receptor		Questions of Benefit-Sharing	427
(IGF1R) Pathway	386	Conclusions	429
The PI3K/AKT/mammalian Target of		Glossary	429
Rapamycin (mTOR) Pathway	386	References	429
Notch, Wnt, and Hedgehog (hh) Pathways	387		
Conclusions	387		
Glossary	388	Part 6	
Abbreviations	388	Future Directions	
References	388		
23. Wilms Tumors		25. The Role of MicroRNAs and	
<i>Elizabeth J. Perlman and Peter Hohenstein</i>		Ultraconserved Non-Coding RNAs	
Wilms Tumors	398	in Cancer	
Renal Development	399	<i>Hui Ling and George A. Calin</i>	
Wilms Tumor Development	400	Introduction	436
WT1	400	MiRNAs and Cancer	436

Deregulated miRNA Expression in Cancer	437	Important Components of the Exposome	457
miRNA Function and Its Involvement		Tobacco	458
in Cancer	438	Dietary, Physical Activity and Overweight	459
miRNAs as Diagnostic Tools	440	Alcohol	460
miRNAs as Therapeutic Options	441	Occupational Exposures	460
UCGs and Cancer	443	Radiation	460
Deregulated UCG Expression in Cancer	443	The Social Environment: Impact on the	
UCGs as Oncogenes or Tumor Suppressors	444	Exposome	461
Conclusion	444	Mechanisms of Environmental Carcinogenesis	461
Glossary	445	Genetic and Epigenetic Change	461
Abbreviations	445	Epigenetics and Environmental	
References	445	Carcinogenesis: Three Examples	462
		Moving Knowledge on Environmental	
		Causes of Cancers Forward: The	
		Role of Omics	463
		Conclusion	463
		Glossary	464
		Abbreviations	464
		References	464
26. The Impact of the Environment			
on Cancer Genomics			
<i>Louise Parker</i>			
Cancer: A Global Disease	450	Abbreviations	467
Cancer Is a Family of Diseases	450	Glossary	473
Cancer Is an Environmental Disease	453	Index	487
Narrow and Broad Definitions of			
Environmental Exposure	453		
The Exposome	454		
Measuring Exposures and Determining			
Causation	456		